<DOC>
	<DOCNO>NCT02439203</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled , 2-way crossover study evaluate efficacy , safety/tolerability pharmacokinetics JM-010 treatment subject Parkinson 's Disease ( PD ) levodopa-induced dyskinesia ( LID ) .</brief_summary>
	<brief_title>Efficacy Safety JM-010 PD With Levodopa-Induced Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Written inform consent . Subject diagnosis moderate severe idiopathic PD show responsiveness levodopa . All antiParkinsonian medication levodopa must stable least 1 week prior start runin period . Subject stable predictable peakeffect LID least 2 hour awake day least moderately disable . Amantadine and/or monoamine oxidase ( MAO ) inhibitor must stop least 2 week prior start Treatment Period 1 ( TP 1 ) . Diagnosis unclear suspicion Parkinsonian syndromes exists , secondary Parkinsonism , Parkinsonplus syndromes neurological degenerative disease . History brain surgery surgery treatment PD . Current primary psychiatric diagnosis acute psychotic disorder primary psychiatric diagnosis . A history psychosis and/or treatment antipsychotic within 3 month prior start Treatment Period 1 ( TP1 ) . A history , current , seizure disorder subject require treatment anticonvulsant . Clinically significant abnormal laboratory data screening . Clinically relevant ischemic heart symptom history myocardial infarction , coronary artery bypass surgery percutaneous transluminal coronary angioplasty , within previous 12 month prior start TP1 . History cerebrovascular accident transient ischemic attack , coronary vasospasm/Prinzmetal 's angina . History serotonin syndrome . Breast feed pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>Levodopa Induced Dyskinesia ( LID )</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>